T-cell surface glycoprotein (CD)

T-cell surface glycoproteins represent a broad class of membrane proteins, predominantly within the Cluster of Differentiation (CD) system, that are fundamental to the orchestration of the adaptive immune response (Janeway's Immunobiology, 9th ed.). Key members such as CD3, CD4, and CD8 act as essential components or co-receptors for the T-cell receptor (TCR) complex, facilitating the recognition of peptide-MHC complexes (UniProt P07766, P01730). These molecules are involved in critical biological processes including signal transduction, cell-cell adhesion, and the regulation of T-cell maturation and activation (StatPearls, "T-Cell Receptors"). In therapeutic contexts, these glycoproteins are targeted by monoclonal antibodies and bispecific engagers to treat conditions ranging from autoimmune diseases like Type 1 Diabetes to various hematologic malignancies (PubMed PMID: 31534168). For instance, CD3-targeting agents like Teplizumab are used to delay the onset of clinical diabetes, while CD4-directed therapies like Ibalizumab are used in multi-drug resistant HIV-1 infections (FDA Label: Tzield, Trogarzo). Despite their therapeutic utility, targeting these glycoproteins often necessitates careful monitoring for safety concerns such as cytokine release syndrome and severe lymphopenia (PubMed PMID: 29606361). This entry is marked as incorrect because the term refers to a broad category of proteins rather than a single specific therapeutic target.

Other names

Cluster of differentiationCD antigenT-cell markerT-cell surface antigenT-cell receptor complex components

Therapeutic agents typically act by binding to specific glycoproteins to either inhibit T-cell activation, deplete specific T-cell subsets, or redirect T-cell cytotoxic activity toward malignant cells (PubMed PMID: 31534168).